Korean J Hematol.  2006 Jun;41(2):134-137. 10.5045/kjh.2006.41.2.134.

Two Cases of Cytomegalovirus Pneumonia after CD34 Selected Autologous Stem Cell Transplantation

• Kwon YL
• Joeng JK
• Kim GY
• Kim SR
• Lee SY
• Youn YD
• Lee JL
• Lee WS
• Kwon GY
• Park JH

• KMID: 2083490
• DOI: http://doi.org/10.5045/kjh.2006.41.2.134

Abstract

Cytomegalovirus (CMV) pneumonia is an important cause of treatment related mortality after allogeneic stem cell transplantation (SCT) and autologous SCT, particularly in a CD34 selected setting. There is little known about the immune reconstitution pertaining to the CMV after CD34 selected SCT. However, several studies have suggested there is more profound immunodeficiency early in the CD34 selected population compared with the unselected population. We encountered two fatal cases of CMV pneumonia at the CD34 selected SCT for T-cell lymphoblastic lymphoma and high-risk breast cancer that was confirmed through a lung biopsy and bronchoalveolar lavage. In conclusion, autologous CD34 selected CMV seropositive recipients need to be monitored in a similar manner to allogeneic recipients.

Keyword

CMV pneumonia; CD34 selected stem cell transplantation; T-cell lymphoblastic lymphoma; Breast cancer

MeSH Terms

Biopsy
Breast Neoplasms
Bronchoalveolar Lavage
Cytomegalovirus*
Lung
Mortality
Pneumonia*
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Stem Cell Transplantation*
Stem Cells*
T-Lymphocytes

Figure

• 

  Fig. 1 There noted infiltration of fibrin along alveolar inner wall with cells that have nucleus and marked nucleoli (H& E stain, ×400).

• 

  Fig. 2 Immunohistochemical stain showed nucleus and cytoplasm infected by CMV (Immunohistochemical stain for CMV, ×400).

• 

  Fig. 3 The consolidation was seen on the upper lobe of right lung field on day 70 post transplant.

Reference

1). Holmberg LA., Boeckh M., Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 1999. 94:4029–35.

2). Konoplev S., Champlin RE., Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001. 27:877–81.

3). Shpall EJ., LeMaistre CF., Holland K, et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood. 1997. 90:4313–20.

4). Bomberger C., Singh-Jairam M., Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood. 1998. 91:2588–600.

5). Wingard JR., Chen DY., Burns WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood. 1988. 71:1432–7.

6). Machado CM., Dulley FL., Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000. 26:413–7.

7). Boeckh M., Nichols WG., Papanicolaou G., Rubin R., Wingard JR., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003. 9:543–58.